pentobarbital will decrease the level or outcome of solifenacin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will minimize the level or effect of dexamethasone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lower the extent or effect of fesoterodine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will minimize the level or result of venetoclax by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
Warning ought to be exercised any time a barbiturate is administered into a nursing woman since modest amounts of barbiturates are excreted in the milk.
Dosage needs to be reduced in the aged or debilitated simply because these patients may be far more sensitive to barbiturates. Dosage must be minimized for individuals with impaired renal perform or hepatic sickness.
pentobarbital decreases levels of vandetanib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of coadministration with strong CYP3A4 inducers; these medication lower exposure to vandetanib by as many as forty%.
pentobarbital will lower the extent or impact of methadone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will decrease the level or result of quetiapine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will lower the level or result of buspirone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will decrease the level or effect of alfuzosin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will reduce the extent or effect of irinotecan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital and olopatadine intranasal here equally boost sedation. Prevent or Use Alternate Drug. Coadministration increases chance of CNS despair, which can result in additive impairment of psychomotor functionality and result in daytime impairment.
Phenobarbital has been proven to shorten the 50 %-life of doxycycline for so long as two weeks just after barbiturate therapy is discontinued. This system is most likely in the induction of hepatic microsomal enzymes that metabolize the antibiotic.